Plcb1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The PLCB1 gene encodes phospholipase C beta 1, a key enzyme in phosphoinositide signaling that is implicated in brain development and neurodegeneration.
| Property |
Value |
| Gene Symbol |
PLCB1 |
| Full Name |
Phospholipase C Beta 1 |
| Chromosomal Location |
20p12.3 |
| NCBI Gene ID |
23236 |
| OMIM |
607120 |
| Ensembl ID |
ENSG00000141642 |
| UniProt |
Q9NQ66 |
PLCB1 encodes phospholipase C beta 1, which hydrolyzes PIP2 to IP3 and DAG, key second messengers in:
- G-protein coupled receptor signaling
- Calcium signaling
- Synaptic transmission
- Neuronal development
PLCβ1 is crucial for neuronal signaling and plasticity.
PLCB1 mutations cause Ohtahara syndrome and other early-onset epileptic encephalopathies[1].
- Autism spectrum disorder
- Intellectual disability
- Neurodegeneration (emerging evidence)
PLCB1 is highly expressed in:
- Brain (cerebral cortex, hippocampus, cerebellum)
- Testis
- Lower levels in other tissues
The study of Plcb1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Yang J, et al. "Phospholipase C-beta signaling in neuronal function." Adv Exp Med Biol. 2020;1131:337-357. PMID:31621042
- Riekenberg S, et al. "PLC-beta isoforms in neuronal signaling." Cell Signal. 2009;21(2):235-244. PMID:19007879
- Hossain MI, et al. "PLCbeta4 in neural development." Dev Neurobiol. 2008;68(10):1312-1324. PMID:18666273
- De S, et al. "PLCB1 and neuropsychiatric disorders." J Neurosci Res. 2021;99(5):1234-1248. PMID: 334Targeted29181
- Kim D, et al. "Phospholipase C in synaptic plasticity." Neuropharmacology. 2017;120:35-44. PMID:28342921
PLCB1 is one of four mammalian PLC-beta isoforms (PLCB1-4). The gene undergoes alternative splicing producing:
- PLCB1a: Full-length version in neurons
- PLCB1b: Truncated variant with modified regulation
Each PLC-beta isoform contains:
- N-terminal PH domain: Membrane targeting via PIP2
- EF-hand domain: Calcium regulation
- X and Y domains: Catalytic core
- C2 domain: Calcium-dependent membrane association
PLCB1 is activated by:
- Muscarinic acetylcholine receptors (M1, M3, M5)
- Glutamate receptors (mGluR1, mGluR5)
- Serotonin receptors (5-HT2)
- Alpha-adrenergic receptors
Upon activation, PLCB1 hydrolyzes PIP2 to generate:
- IP3: Releases calcium from ER stores
- DAG: Activates protein kinase C (PKC)
PLC-beta signaling is crucial for:
- Long-term potentiation (LTP)
- Long-term depression (LTD)
- Dendritic spine morphology
- AMPA receptor trafficking
The IP3/Ca2+ pathway regulates:
- Gene transcription via CaMKIV
- Neurotransmitter release
- Dendritic growth
- Synapse formation
¶ Learning and Memory
Mouse models show:
- PLCB1 knockout: Impaired spatial learning
- Reduced LTP in hippocampal slices
- Memory consolidation deficits
- PLCB1 mutations associated with epileptic encephalopathy
- Dysregulated PLC signaling contributes to hyperexcitability
- Altered calcium homeostasis in seizure circuits
- APP/Abeta affects PLC signaling pathways
- Impaired PLC activity in AD brains
- Potential therapeutic target
- Dopamine receptor-mediated PLC activation
- Altered signaling in PD models
- Interaction with alpha-synuclein
- PLCB1 variants found in ID patients
- Defects in neuronal development
- Synaptic plasticity impairments
- Mecamylamine: Nicotinic antagonist, affects PLC signaling
- U73122: PLC inhibitor (research use)
- Lithium: Modulates PLC pathways indirectly
- PLC-beta activators: Cognitive enhancement
- PLC-beta inhibitors: Anticonvulsant potential
- Subtype-selective modulators in development
- Knockout mice: Show severe neurological phenotypes
- Conditional knockouts: Brain-region specific studies
- Transgenic overexpression: Disease modeling
Last updated: 2026-03-04